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ABSTRACT
The MutationAligner web resource, available at http://
www.mutationaligner.org, enables discovery and ex-
ploration of somatic mutation hotspots identified in
protein domains in currently (mid-2015) more than
5000 cancer patient samples across 22 different tu-
mor types. Using multiple sequence alignments of
protein domains in the human genome, we extend the
principle of recurrence analysis by aggregating mu-
tations in homologous positions across sets of par-
alogous genes. Protein domain analysis enhances
the statistical power to detect cancer-relevant muta-
tions and links mutations to the specific biological
functions encoded in domains. We illustrate how the
MutationAligner database and interactive web tool
can be used to explore, visualize and analyze muta-
tion hotspots in protein domains across genes and
tumor types. We believe that MutationAligner will be
an important resource for the cancer research com-
munity by providing detailed clues for the functional
importance of particular mutations, as well as for
the design of functional genomics experiments and
for decision support in precision medicine. Mutation-
Aligner is slated to be periodically updated to incor-
porate additional analyses and new data from cancer
genomics projects.
INTRODUCTION
Through major tumor profiling projects, such as the The
Cancer Genome Atlas (TCGA), it is becoming clear that
the mutational landscape in cancer is extraordinarily com-
plex (1). Recent analysis of mutations across cancer types
(‘pan-cancer’ analysis) has revealed that relatively few genes
are recurrently mutated in a high proportion of samples
(2) above expectation from a random distribution without
clonal selection. These genes are hypothetical or known
cancer genes. At the other end of the spectrum there ex-
ists a long tail of infrequently mutated genes (3). For such
rare mutations, recurrence analysis is insufficient to distin-
guish functional mutations from background passenger al-
terations. In some cases prior independent knowledge of
the oncogenic potential of rare mutations is available, but
in many cases such knowledge is borderline or not avail-
able. Enhancing the computational-analytic methods for
establishing the identity of infrequent mutations that play
causative roles in cancer is not only an important scientific
question for understanding tumorigenesis, but is also essen-
tial to the development of personalized cancer therapies.
A clue to understanding the potential consequence of in-
frequent mutations may come from analyzing genetic alter-
ations across genes involved in similar biological processes.
One powerful method for systematically assessing the com-
mon biological functions of genes is through the analysis of
protein domains. Protein domains are evolutionarily con-
served and structurally related functional regions encoded
in the primary sequence of proteins (4,5). Proteins with
shared domains (protein families) have a high degree of se-
quence similarity, which is often detected and analyzed us-
ing multiple sequence analysis and hidden Markov models
(HMMs). Large repositories of information about protein
domains include the manually curated database for protein
families (Pfam-A), which contains sequence information as
well as annotations about the known biological roles and
functions of domains in various species (6).
To address the critical challenge of associating function
with rare mutations in cancer, we present a comprehensive
web-based resource of the analysis of mutations in protein
domains in cancer. This resource, called ‘MutationAligner’,
is associated with our recent work describing a new analyt-
ical framework that uses domains, rather than individual
genes, as the basis for the discovery of functionally relevant
mutations in cancer (7). MutationAligner enhances statis-
tical power by aggregating mutations across sets of genes
sharing a common domain. In doing so, the website also
*To whom correspondence should be addressed. Tel: +44 1223 769 500; Fax: +44 1223 404 208; Email: mutalign@gmail.com
Correspondence may also be addressed to Nicholas Paul Gauthier. Tel: +1 646 888 2610; Fax: +1 646 422 0717; Email: mutalign@gmail.com
Correspondence may also be addressed to Chris Sander. Tel: +1 646 888 2602; Fax: +1 646 422 0717; Email: mutalign@gmail.com
C© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
 at U
niversity of Cam
bridge on January 20, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016, Vol. 44, Database issue D987
enables novel hypothesis generation by associating rare mu-
tations of unknown function with well-characterized muta-
tions in homologous domain positions.
In previous work, we and others have utilized the se-
quence similarity encoded in domains to discover ‘domain
hotspots’, which can be defined as recurrent mutations af-
fecting conserved residues in 3D structures or conserved po-
sitions in multiple sequence alignments of protein domains
(7–9). In the MutationAligner approach (7), we system-
atically analyzed nearly 500 000 missense mutations from
22 TCGA-profiled tumor types deposited in the cBioPor-
tal (10) by tallying mutations across sequence alignments
of protein domains. We implemented a binomial statistical
test to identify significant domain hotspots. Yue et al. de-
veloped the ‘mCluster’ approach (http://research-pub.gene.
com/mcluster) in which around 9000 somatic cancer muta-
tions, 19 000 germline disease mutations and 17 000 other
annotations of amino acid residues were analyzed in the
context of sequence alignments of domains (9). mCluster
uses similar binomial statistics to identify domain hotspots
or ‘clusters’, except mCluster performs the cluster detection
using a step-down approach analyzing the position with
the largest number of mutations first followed by the next
largest and so forth. In the ‘DMDM’ (Domain mapping
of disease mutations) approach, Peterson et al. analyzed
around 100 000 polymorphisms and disease mutations in
domains (8). The data are presented at http://bioinf.umbc.
edu/dmdm/ using sequence logo plots of aligned domains
and associated histograms of mutation counts, although no
statistics are provided. Due in part to the scarcity of data
available at the time of analysis, the mCluster and DMDM
methods did not include a systematic pan-cancer analy-
sis of mutation hotspots in domains. Other bioinformat-
ics analyses of mutations in domains performed more re-
cently (11–13) have focused on characterizing and identi-
fying mutations enriched across the full length of domains
and do therefore not include multiple sequence analysis and
hotspot detection across domain-containing genes.
In this work, we (i) describe the MutationAligner
database and how other resources are combined and inte-
grated (Pfam-A, cBioPortal and TCGA) (1,6,10), (ii) pro-
vide technical details about the database construction and
software architecture and (iii) provide guidelines and illus-
trate with an example of how exploring the database can
reveal biological insights of mutations in domains in can-
cer. The web resource is linked to the cBioPortal for can-
cer genomics data and is freely available at http://www.
mutationaligner.org. We believe that MutationAligner will
be a valuable resource to computational, experimental and
clinical cancer researchers.
DATABASE CONSTRUCTION AND SOFTWARE AR-
CHITECTURE
Data collection and analysis
The data and analysis pipeline behind theMutationAligner
database is illustrated in Figure 1A and is described in detail
elsewhere (7). Briefly, around 460 000 missense mutations
from 5496 exome-sequenced tumor-normal pairs of 22 dif-
ferent tumor types studied by the TGCA consortium were
obtained from the cBioPortal (10) in the format of TCGA
Figure 1. Database construction and software architecture of
mutationaligner.org. (A) Integrated analysis of cancer mutations
from TCGA and protein domains from Pfam-A. (B) Identified domain
mutation hotspots and analysis results are stored and served from a
python webserver via a documented Application Programming Interface
(API, see main text). The webserver also provides the files required for
the single page javascript application. (C) Analysis results are provided
interactively in the user’s web browser (client-side) through a rich,
single page javascript application. (D) Examples of potential follow-on
applications based on observations made using MutationAligner.
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level 3 variant data. Missense mutations were mapped to
protein sequences and protein domains annotated by Pfam-
A version 26 (6). Pfam-A domains were excluded from the
analysis if (i) no missense mutations were present, (ii) the
Pfam-A expectancy score (e-value) was greater than 1e−5 or
(iii) the domain was only present as one instance in the hu-
man genome. In total, 4401 Pfam-A domains were analyzed
by multiple sequence alignment of domain regions across
protein families using the MathWorks multialign package
with BLOSUM80 as scoringmatrix and default parameters.
As sequences of domains in paralogous genes within the
same species (human) are closely related, the BLOSUM80
matrix was chosen as it is designed for comparing less di-
vergent sequences than other matrices (e.g. BLOSUM45).
Mutations were tallied across samples and across domain-
containing genes using the coordinates of the multiple se-
quence alignment. To identify putative hotspots for muta-
tions within a domain, we used a binomial test, taking into
account the length and total number of mutations observed
in the domain. This test generated a P-value by compar-
ing the number of mutations observed at that domain posi-
tion to what would be observed by chance assuming a ran-
dom distribution of mutations. In total, 17 273 positions in
the domain sequence alignments (‘positions’) were analyzed
based on the following criteria: (i) at least two missense mu-
tations occurred at each position and (ii) at least three quar-
ters of the domain alignments were non-gaps at each po-
sition. All P-values were adjusted for multiple hypothesis
testing using the stringent Bonferroni correction method.
We identified 82 significant (adjusted P < 0.05) hotspots in
42 different domains (7).
Webserver and application programming interface (API)
The primary function of the MutationAligner webserver is
to deliver a single HTML, javascript and cascading style
sheet (Cascading Style Sheet) file to client web browsers (see
Interactive Client-Side below). In addition, the website pro-
vides data access to other software systems through a repre-
sentational state transfer (REST) application programming
interface (API). This REST API returns Javascript Object
Notation (JSON) files and currently supports the following
three methods:
(1) http://mutationaligner.org/api/positions
Returns a single object with details of all analyzed posi-
tions.
(2) http://mutationaligner.org/api/domains
Returns an array containing a list of all domains ana-
lyzed that contain an interactive domain details page.
(3) http://mutationaligner.org/api/domains/domainname
Returns a single object for the domainname entered or
Not Found error (HTTP 404) if the domain does not ex-
ist or was not analyzed. Both Pfam accession codes and
domain names are supported.
Documentation about each JSON format is available at
http://mutationaligner.org/API.
Interactive user interface
All data interaction and visualization are driven by a rich
Single Page Application (SPA) powered by the AngularJS
javascript framework. The website provides several views
for browsing and interacting with the analysis results and
the raw mutation data. Upon visiting mutationaligner.org,
users are presented with a browsable table that contains in-
formation and key analysis results for all analyzed posi-
tions. This table is populated from the positions JSON file
(see API#1 above). Typing into the search box dynamically
updates the table to display positions that contain muta-
tions in particular genes, cancer types or domains of in-
terest. Clicking on the domain name or chart icon of any
position loads the domain details page. This page is pop-
ulated from the requested domain’s JSON file (see API#3
above), and allows users to display and interact with muta-
tional profiles of individual domains. Mutation histograms
are produced in Scalable Vector Graphics (SVG) format
with the D3 javascript library, and the multiple sequence
alignments are drawn with custom canvas drawing code.
The website has been tested with the latest version of all ma-
jor browsers (Firefox, Google Chrome, Internet Explorer
and Safari).
EXPLORING MUTATION HOTSPOTS IN DOMAINS
MutationAligner can be used interactively as a resource to
explore and analyze the incidence of mutations across func-
tionally related genes. In order to highlight some of the fea-
tures of the website, we describe a typical use case scenario
of a researcher interested in a particular gene (the Kelch 1
domain-containing gene KEAP1) and its role in cancer.
TheKEAP1 gene regulates the transcription factorNRF2
by acting as a substrate adaptor protein for the Cul3-RBX1
E3-ubiquitin ligase complex (14). KEAP1 is cysteine-rich,
and modification of cysteine residues due to oxidative stress
can induce a conformational change in KEAP1, leading
to the nuclear translocation of NRF2 and up-regulation
of anti-oxidant stress response genes (15). KEAP1 is com-
posed of a series of six repeated Kelch 1 domains, and the
mutation of residues in this domain have been shown to lead
to dysregulated activation of NRF2 (14).
The Kelch 1 domain encodes a Kelch motif, typically
composed of ≈40–50 amino acids, which form a four-
stranded -sheet. Kelch motifs are typically arranged in
a series of tandem repeats, which then organize into a -
propeller tertiary structure often mediating protein-protein
interactions (16).
Search & explore
On the mutationaligner.org homepage, users can query a
searchable and sortable table with all mutations analyzed in
the context of protein domains, providing an effective way
of identifying domain mutations in specific genes or tumor
types of interest (Figure 2A).
The table of all analyzed positions (positions tab) is dy-
namically updated to show matching search results of the
>17K domain mutations analyzed and provides the user
with information about (i) the specific position in the multi-
ple sequence alignment that is mutated; (ii) the hotspot sig-
 at U
niversity of Cam
bridge on January 20, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016, Vol. 44, Database issue D989
Figure 2. Interactive exploration of mutation hotspots in protein domains.
(A) Searchable and sortable tables of all domainmutation hotspots by posi-
tions, domains and genes. (B) Domain details page with multiple sequence
alignment and interactive mutation histograms.
nificance level (–log10 of theP-value); (iii) the entropy score
that estimates how uniformly mutations are spread across
domain-containing genes, where a high score indicates that
multiple genes are mutated in the particular position (the
entropy score is normalized to the domain family size, with
a maximum score of 1 signifying that mutation counts are
the same for all genes); (iv) the number of identified mu-
tations; (v) information on which genes are mutated; (vi)
information on which cancer types are mutated (7).
In addition to the positions tab, the domains tab and
genes tab provide users with an option to browse and search
for particular domains and genes. The statistics provided for
these tabs are similar to those described above, except only
the position with the best P-value or highest entropy score
(adjustable via a toggle button) is displayed. Of note, not
all domains and genes in the human genome are listed as
some domains, genes and mutations were filtered out using
the exclusion criteria stated in Data Collection and Analy-
sis section. For example, canonical hotspots in well-known
cancer-associated genes, such as APC, may not be included
as either the mutation type was not analyzed (e.g. truncat-
ingmutationswere excluded) and/or therewere nomissense
mutation hotspots in Pfam-A annotated domains within
the gene.
To facilitate browsing and exploration, all analyzed data
can be ranked by clicking and sorting the columns to inspect
particular mutations of interest. In the Kelch 1 domain, for
example, position 12 is found as themost significant hotspot
with mutations in multiple genes including KEAP1. That
mutations in position 12 are contributed by multiple genes
is also indicated by the relatively high entropy score (∼0.5),
which may indicate that this particular hotspot is difficult
to detect using a gene-based approach but only revealed in
the context of a domain analysis.
To explore the mutations in Kelch 1 further, users can
click on the domain name or chart icon (Figure 2A, bot-
tom), bringing the user to the domain details page.
Visualize & analyze
The details page of user-selected domains visualizes muta-
tions in the context of domain sequence alignments and al-
lows users to analyze mutations across selected genes and
tumor types.
Figure 2B depicts a typical domain details page summa-
rizing information for mutations in the selected Kelch 1 do-
main. The header of the details page lists the name of the
domain and contains relevant information such as the do-
main description and links to Pfam and InterPro (17). A
summary histogram at the top of the page depicts the dis-
tribution of aligned mutations, summed across all cancer
types over all genes containing the Kelch 1 domain (oc-
curs 116 times in 43 genes). The color of each unit box in
the histogram indicates the identity of the new amino acid
that is generated by the missense mutation. Amino acids
are grouped and color coded by their biochemical prop-
erties, enabling user to identify general patterns of muta-
tional changes. For example, in the tallest peak (position
12), a large proportion of the new amino acids generated
by mutations are positively charged, basic amino acids (R
andK, red) and cysteines (C, yellow). All histograms are in-
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teractive, displaying summary data tables upon mouseover
and highlighting particular positions across all currently
displayed charts in response to user clicks. This highlight
makes it easy to compare aligned positions in different
genes and cancer types. To display gene-specific sequence
coordinates when hovering over the domain positions in the
mutation histograms, the user can select genes of interest via
the ‘display gene positions’ option.
For illustrative purposes, we have selected the most
prominant peak in the Kelch 1 domain, which occurs at
position 12 of the multiple sequence alignment (red dot-
ted line in Figure 2B). The peak at position 12 is an ag-
gregate of homologous mutations of the Kelch 1 domain
across multiple genes. Among eight genes that have muta-
tions in position 12, KEAP1 has the most mutations, which
can be displayed in more detail using the ‘Select gene’ op-
tion (note that only five of the six Kelch 1 domains in
KEAP1 were analyzed as the first instance was excluded
based on high e-value). DisplayingKEAP1’s fourthKelch 1
domain, which spans amino acid positions 459–504, shows
six mutations in residue R470 with four being R470C mu-
tations. The KEAP1 R470C mutation has been reported
as a ‘super-binder’ in the literature, leading to enhanced
KEAP1 andNRF2 interaction and hypomorphic regulation
of NRF2 by KEAP1 (18). Interestingly, two mutations oc-
cur in KEAP1 at position G423 in the third Kelch 1 repeat
(residues 412–457), and these align precisely with the R470
mutation hotspot. As these two repeats are mutated at anal-
ogous positions andmultiple repeats are needed to form the
functional Kelch 1 -propeller, these observations indicate
that G423 mutations are likely functionally relevant despite
being rare mutation events. Supporting this, Hast et al. have
reported that the non-canonical G423 mutation in KEAP1
has an identical ‘super-binder’ effect as theR470Cmutation
(18).
By using the ‘Select cancers’ option, users can view the
distribution of mutations for individual tumor types. For
Kelch 1 this view shows that lung cancers in general have
many mutations distributed over the domain. For position
12 specifically, lung squamous cell carcinoma (LUSC) has
six mutations (LUSC, Figure 2B) while lung adenocarci-
noma (LUAD) has three with the majority of these position
12 mutations being in KEAP1. Accordingly, KEAP1 has
previously been reported as significantly altered in large-
scale sequencing projects in lung adenocarcinoma (19) and
lung squamous cell carcinoma (20),
Discover
TheMutationAligner tool offers the possibility to draw new
and unexpected links between observations of mutations
across different genes as mutations may often affect equiv-
alent residues of domains of paralogous genes. Analyzing
mutations across different user-selected tumor types also of-
fers the ability to transfer knowledge from one context to
another, particularly when recurrent mutations in one can-
cer type overlaps with more infrequent mutations in other
cancer types.
For example, in the case of Kelch 1, while most muta-
tions at position 12 were in lung cancer, using Mutation-
Aligner it is clear thatmelanomas (SKCM) also containmu-
tations in the same position (five mutations, Figure 2B). To
examine the details of individual mutations in SKCM, one
can mouseover the position and see the mutated genes, cor-
responding residues and samples. Interestingly, out of the
five mutations found in melanoma in position 12, none of
the mutations occur in KEAP1, but rather these mutations
are spread across KLHL4 (three mutations), KLHL18 and
KLHL20 (see box in Figure 2B). These KLHL genes were
not highlighted in a recent cancer genomics marker paper
on melanoma by the TCGA consortium (21).
The color coded multiple sequence alignment on the bot-
tom of the domain details page reveals that the Kelch 1 do-
main has a high degree of sequence similarity across par-
alogous genes in the human genome. Thus, based on the
structure-function relationship encoded Kelch 1, this indi-
cates that the rare mutations in melanoma (e.g. KLHL4
G523R) could alter Kelch 1-mediated function as they af-
fect equivalent positions to the canonical KEAP1 hotspot
mutations reported in lung cancer. Taken together, the ob-
servation that mutations in the Kelch 1 domain of KLHL4
align precisely with hotspot mutations in KEAP1, in tan-
dem with a lack of reports of oncogenic mutations in
KLHL4 in melanoma, make these mutations an appealing
subject for future investigation.
DISCUSSION
The end-product of tumor sequencing pipelines is a list of
mutations of putatively unknown consequence. Distilling
meaning from this list, by annotating variants with their
likely contribution to the malignancy, is critical to under-
standing cancer biology and designing therapeutic proto-
cols. While the TCGA has succeeded in identifying many
recurrent alterations in tumors, a number of studies have
highlighted the ‘long tail’ phenomenon in cancer where
many genes are infrequently mutated, making it difficult
to distinguish between non-functional passenger mutations
and true oncogenic driver mutations (2,3,22).
In this work, we present MutationAligner, a rich web re-
source that allows researchers to search, browse and ana-
lyze cancer mutations in the context of protein domains. By
taking a domain-centric approach, we identify new muta-
tion hotspots in domains of genes not previously associated
with cancer and predict the functional role ofmany raremu-
tations (7). With the current data set of 22 tumor types and
5496 samples (mid-2015) we have identified 82 significant
domain hotspots. This number is likely to increase as we
further develop the analysis methodology and as more tu-
mor types and samples become available.
As an example of the utility of the resource, we show
how canonical hotspot mutations in KEAP1 in lung can-
cer align with rare, and putatively functional, mutations in
other Kelch 1-containing genes in melanoma. We believe
that users will discover other relevant domain mutations,
providing interesting hypotheses for further experimental
followup, for example investigating the effect of mutations
at the signaling pathway level and understanding how such
knowledge can be applied clinically (Figure 1D). As more
cancers are sequenced this frameworkwill help point to new
alterations in domains with potential functional impact.
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We plan several future directions for MutationAligner.
First, we plan to add several features such as displaying the
domain structure for individual genes. Second, we plan to
strengthen the connection with the cBioPortal for cancer
genomics data. Although bidirectional hyperlinks have al-
ready been established, we would like to integrate more con-
text dependent linking. For example, we would like to pro-
vide a mechanism by which cBioPortal can embed (for par-
ticular genes or cancer types) mutation histograms and do-
main sequence alignments generated by MutationAligner.
Finally, we will continuously update the website with new
analyses and cancer genomics data as they become avail-
able.
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